A 73-year-old woman on chronic levothyroxine therapy has a TSH of 5.96 mIU/L with normal free thyroxine and free triiodothyronine; how should her hypothyroidism be managed?

Management of Elevated TSH in a 73-Year-Old Woman on Chronic Levothyroxine Therapy

Increase the Levothyroxine Dose

Your patient's TSH of 5.96 mIU/L indicates inadequate thyroid hormone replacement, and you should increase her levothyroxine dose by 12.5–25 mcg to normalize her TSH into the target range of 0.5–4.5 mIU/L. 1

---

Why This Patient Needs Dose Adjustment

Current Thyroid Status

• TSH 5.96 mIU/L is above the normal reference range (0.45–4.5 mIU/L), confirming inadequate replacement despite normal free T4 and T3 1
• In patients already on levothyroxine therapy with TSH in the 4.5–10 mIU/L range and normal free T4, dose adjustment is reasonable to normalize TSH into the reference range 1
• Even with subclinical hypothyroidism (elevated TSH, normal free T4), treatment is reasonable when the patient is already on thyroid replacement therapy 1

Risks of Undertreatment at This TSH Level

• Persistent TSH elevation >7 mIU/L (though your patient is at 5.96) indicates inadequate replacement and carries risk of progression to overt hypothyroidism at approximately 5% per year 1
• Undertreatment risks include persistent hypothyroid symptoms, adverse effects on cardiovascular function, lipid metabolism, and quality of life 1
• Hypothyroidism causes cardiac dysfunction including delayed relaxation and abnormal cardiac output, which may manifest as reduced functional capacity 1

---

Specific Dosing Strategy for This 73-Year-Old Patient

Initial Dose Increase

• Increase levothyroxine by 12.5–25 mcg based on her current dose and clinical characteristics 1
• For patients >70 years or with cardiac disease, use smaller increments (12.5 mcg) to avoid potential cardiac complications 1
• Larger adjustments may lead to overtreatment and should be avoided, especially in elderly patients or those with cardiac disease 1

Age-Specific Considerations

• For patients over 70 years old, especially those with cardiac disease or multiple comorbidities, more conservative titration is appropriate using 12.5 mcg increments 1
• Start with 12.5 mcg increase if she has any cardiac history, risk factors, or frailty; use 25 mcg if she is otherwise healthy and robust 1

---

Monitoring Protocol After Dose Adjustment

Timing of Follow-Up Testing

• Recheck TSH and free T4 in 6–8 weeks after dose adjustment to evaluate the response 1, 2
• Levothyroxine requires 6–8 weeks to reach steady state, so earlier testing will not accurately reflect the new dose 1
• Free T4 can help interpret ongoing abnormal TSH levels during therapy, as TSH may take longer to normalize 1

Target Goals

• Target TSH should be within the reference range (0.5–4.5 mIU/L) with normal free T4 levels 1
• For elderly patients, TSH values slightly higher (up to 5–6 mIU/L) may be acceptable to avoid overtreatment risks, though this is not universally agreed upon 1

Long-Term Monitoring

• Once adequately treated, repeat testing every 6–12 months or if symptoms change 1, 2
• Monitor TSH annually or sooner if the patient's clinical status changes once the appropriate maintenance dose is established 1

---

Critical Pitfalls to Avoid

Overtreatment Risks

• Avoid excessive dose increases that could lead to iatrogenic hyperthyroidism, which increases risk for osteoporosis, fractures, abnormal cardiac output, and ventricular hypertrophy 1
• Approximately 25% of patients on levothyroxine are unintentionally maintained on doses sufficient to fully suppress TSH, increasing risks for atrial fibrillation, osteoporosis, and cardiac complications 1, 3
• Development of low TSH (<0.1–0.45 mIU/L) on therapy suggests overtreatment; dose should be reduced with close follow-up 1

Cardiac Monitoring in Elderly Patients

• For patients with atrial fibrillation, cardiac disease, or other serious medical conditions, more frequent monitoring may be warranted—consider repeating testing within 2 weeks if cardiac symptoms develop 1
• Elderly patients with coronary disease are at increased risk of cardiac decompensation, even with therapeutic doses of levothyroxine, which can unmask or worsen cardiac ischemia 1

Confirming Persistent Elevation

• Before making significant dose changes, ensure TSH elevation is persistent by confirming with repeat testing, as 30–60% of elevated TSH levels normalize spontaneously 1
• However, in a patient already on chronic levothyroxine therapy, a TSH of 5.96 mIU/L clearly indicates inadequate dosing rather than transient elevation 1

---

Special Considerations for This Patient

Exclude Interfering Factors

• Review medication adherence: Confirm she is taking levothyroxine on an empty stomach, 30–60 minutes before breakfast 1
• Check for interfering medications: Iron, calcium supplements, proton pump inhibitors, and certain other drugs can impair levothyroxine absorption 1
• Assess for recent iodine exposure (e.g., CT contrast), which can transiently affect thyroid function tests 1

Consider Autoimmune Etiology

• If not previously done, measure anti-TPO antibodies to confirm autoimmune etiology (Hashimoto's thyroiditis), which predicts higher progression risk (4.3% per year vs 2.6% in antibody-negative individuals) 1
• Positive TPO antibodies identify an autoimmune etiology for thyroid dysfunction, with higher risk of progression to overt hypothyroidism 1

Assess for Adrenal Insufficiency (If Suspicion Exists)

• In patients with suspected central hypothyroidism or concurrent adrenal insufficiency, start corticosteroids before increasing levothyroxine to prevent precipitating adrenal crisis 1
• However, this patient's elevated TSH with normal free T4 confirms primary (not central) hypothyroidism, so adrenal assessment is not routinely needed unless clinical features suggest it 1

---

Alternative: When NOT to Treat

Scenarios Where Observation May Be Appropriate

• For asymptomatic patients with TSH 4.5–10 mIU/L and normal free T4 who are NOT already on levothyroxine, routine treatment is not recommended; monitoring every 6–12 months is suggested 1
• However, your patient is already on levothyroxine therapy, so dose adjustment is appropriate to achieve target TSH 1

Evidence Quality

• The evidence supporting treatment for subclinical hypothyroidism with TSH >10 mIU/L is rated as "fair" by expert panels, with potential benefits of preventing progression outweighing risks 1
• For TSH 4.5–10 mIU/L, evidence for treatment benefits is less consistent, but in patients already on therapy, normalization is reasonable 1

---

Summary Algorithm

1. Confirm TSH elevation is persistent (though in a patient on chronic therapy, 5.96 mIU/L clearly indicates underdosing) 1
2. Increase levothyroxine by 12.5 mcg (if elderly/cardiac risk) or 25 mcg (if otherwise healthy) 1
3. Recheck TSH and free T4 in 6–8 weeks 1, 2
4. Adjust dose further if needed by 12.5–25 mcg increments until TSH is 0.5–4.5 mIU/L 1
5. Once stable, monitor TSH every 6–12 months 1, 2
6. Watch for signs of overtreatment (palpitations, tremor, weight loss, TSH <0.45 mIU/L) and reduce dose if they occur 1